Group 1 - The core issue revolves around the ongoing legal disputes between the company and Jingchuan Diagnosis, stemming from the acquisition of a 56.98% stake in Jingchuan Diagnosis in 2020, which has not been resolved satisfactorily [1][2] - The company received a final judgment from the Wuhan Intermediate People's Court, which upheld the lower court's decision requiring Jingchuan Diagnosis to provide access to various corporate documents and financial reports dating back to July 21, 2020 [3] - The management of Jingchuan Diagnosis has been accused of obstructing the company's operations, leading to a suspension of production activities, which the company disputes, claiming that their actions were misrepresented [2] Group 2 - The acquisition agreement included performance commitments for Jingchuan Diagnosis, which were reportedly met, but subsequent disputes over the transfer of remaining shares have led to ongoing litigation [1][2] - The company has faced challenges in obtaining financial data from Jingchuan Diagnosis, hindering internal audits and compliance with legal obligations [2][3] - The legal proceedings highlight the complexities and risks associated with mergers and acquisitions in the healthcare sector, particularly regarding post-acquisition integration and management conflicts [1][2][3]

证券代码：603387 证券简称：基蛋生物 公告编号：2025-027 基蛋生物科技股份有限公司 关于公司涉及诉讼的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 是否会对上市公司损益产生影响：本次诉讼判决为终审判决，不涉及具 体诉讼金额，预计不会对公司本期利润或期后利润产生影响。公司将关注诉讼后 续进展情况并及时履行信息披露义务，敬请广大投资者理性投资，注意投资风险。 一、本次诉讼的基本情况 基蛋生物科技股份有限公司（以下简称"公司"或"基蛋生物"）作为武汉 景川诊断技术股份有限公司（以下简称"景川诊断"）的控股股东，因股份转让 纠纷事项与景川诊断沟通不顺畅，公司无法了解景川诊断的经营情况，无法取得 景川诊断的相关财务数据，内部审计无法开展。为维护公司作为景川诊断控股股 东的法定知情权，基蛋生物作为原告，向景川诊断提起诉讼,诉讼机构名称为武 汉东湖新技术开发区人民法院，诉讼机构所在地为武汉市。 （一）原告诉讼请求 2024 年 12 月，公司收到武汉东湖新技术开发区人民法院送达的《受理案件 通知书》 ...

最新一期业绩显示，2025年一季报，公司实现营业收入2.44亿元，同比-24.08%；净利润6430.74万元， 同比-25.24%，销售毛利率77.15%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13基蛋生物22.2520.091.6744.93亿行业平均 54.3250.504.72116.17亿行业中值38.1137.682.7056.52亿1九安医疗10.9911.120.87185.49亿2新华医疗 15.9814.821.30102.47亿3英科医疗16.0817.331.43254.01亿4山东药玻16.1016.151.85152.30亿5振德医疗 16.4615.511.0559.74亿6奥美医疗16.5616.231.7059.84亿7康德莱17.8617.871.4838.48亿8九强生物 17.9416.682.2088.83亿9维力医疗18.0819.322.2742.38亿10奥泰生物18.1519.131.4757.88亿11鱼跃医疗 19.9219.542.69352.87亿12安图生物20.2719.352.60231.08亿 股东方面，截至2025年3月31 ...

Core Viewpoint - The stock of Jiedan Bio closed at 8.65 yuan, up 1.88%, with a rolling PE ratio of 21.72, marking a new low in 76 days, and a total market capitalization of 4.387 billion yuan [1] Company Summary - Jiedan Bio primarily engages in the research, production, sales, and service of in vitro diagnostic reagents and instruments, recognized as a key high-tech enterprise under the National Torch Program [1] - The company is a major supplier in the domestic in vitro diagnostic field, particularly in the POCT sector, with its main products being self-developed POCT in vitro diagnostic reagents and supporting instruments [1] - The latest quarterly report for Q1 2025 shows the company achieved operating revenue of 244 million yuan, a year-on-year decrease of 24.08%, and a net profit of 64.31 million yuan, down 25.24%, with a gross profit margin of 77.15% [1] Industry Summary - The average PE ratio for the medical device industry is 54.56, with a median of 37.54, placing Jiedan Bio at 47th in the industry ranking [2] - The static PE ratio for Jiedan Bio is 19.62, and the price-to-book ratio is 1.63 [2] - The average market capitalization for the industry is 11.396 billion yuan, with Jiedan Bio's market cap at 4.387 billion yuan [2]

Core Insights - The in vitro diagnostics (IVD) industry is a crucial component of modern healthcare, providing essential data for disease prevention, diagnosis, and treatment through various testing methods [1][5][10] - China's IVD market has surpassed 120 billion yuan in 2024, with a projected growth to 165 billion yuan by 2029, reflecting a compound annual growth rate of 5-8% [1][10][19] - The industry is experiencing significant domestic substitution, with over 80% of Class III diagnostic products being domestically produced, while the share of imported products has decreased from 29.3% to 19.5% from 2021 to 2024 [1][14] Industry Overview - IVD encompasses several testing methods, including biochemical, immunological, molecular, microbiological, blood diagnostics, and point-of-care testing (POCT) [2][5] - The industry is transitioning from scale expansion to high-quality development, driven by government policies and technological innovations [5][21] Policy and Regulatory Environment - Recent government policies, such as the "14th Five-Year Plan for Bioeconomic Development" and the "Comprehensive Action Plan for Improving Medical Quality (2023-2025)," provide a strong impetus for the IVD industry [5][7] - The introduction of the "List of In Vitro Diagnostic Reagents Exempt from Clinical Trials (2025)" has expanded the range of products available in the market [7] Market Dynamics - The IVD industry is characterized by a multi-tiered market structure, with foreign giants dominating the high-end market and domestic leaders gradually increasing their market share [15][19] - The competitive landscape is evolving, with leading companies like Mindray Medical and New Industry Bio showing strong performance, while former leaders in COVID-19 testing, such as Da An Gene and BGI, are seeking business transformation [19][20] Growth Trends - The IVD industry is witnessing a shift towards precision and intelligent diagnostics, with advancements in molecular diagnostics, chemiluminescence, and POCT technologies [21][22] - The integration of AI and big data is enhancing diagnostic efficiency, while the demand for home health management and early cancer screening is rising due to an aging population [21][24] Competitive Landscape - The first tier of the market is dominated by international giants like Roche and Abbott, while domestic leaders such as Mindray and New Industry Bio are gaining traction in immunological and molecular diagnostics [15][19] - The market is seeing increased consolidation, with leading companies acquiring smaller firms to enhance their technological capabilities [23] Registration and Product Development - The registration of IVD products has been robust, with a compound annual growth rate of 25.3% from 2021 to 2024, indicating a vibrant development in the sector [14] - In 2024, the registration of domestic Class III diagnostic products reached 533, accounting for 80.5% of total IVD product registrations [14]

证券代码：603387 证券简称：基蛋生物 公告编号：2025-026 基蛋生物科技股份有限公司 关于公司涉及诉讼的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 是否会对上市公司损益产生影响：本案件二审已立案审查，尚未开庭， 也未产生有效判决，暂时无法判断对公司本期利润和期后利润的影响。公司将根 据诉讼进展情况及时履行信息披露义务，敬请广大投资者理性投资，注意投资风 险。 一、本次诉讼的基本情况 基蛋生物科技股份有限公司（以下简称"基蛋生物"或"公司"）于 2020 年完成对武汉景川诊断技术股份有限公司（以下简称"景川诊断"）的收购，成 为其控股股东。公司作为收购人就避免与景川诊断（含其子公司）构成同业竞争， 在《收购报告书》中承诺自承诺函出具日起，以及作为景川诊断的第一大股东期 间，将不在中国境内外直接或间接从事或参与任何与景川诊断现有主营业务相竞 争的业务及活动，或拥有与景川诊断存在竞争关系的任何经济实体、机构、经济 组织的权益。 原告武汉众聚成咨询管理有限责任公司（以下简称"武汉众聚成"）认为 ...

Group 1 - The core viewpoint of the news highlights the current performance and market position of the company, Jidan Biotechnology, in the medical device industry, noting its low PE ratio compared to industry averages [1] - As of July 16, Jidan Biotechnology's closing price was 8.38 yuan, with a PE ratio of 21.05, marking a new low in 70 days, and a total market capitalization of 4.25 billion yuan [1] - The company ranks 48th in the medical device industry, which has an average PE ratio of 51.87 and a median of 37.48 [1] Group 2 - Jidan Biotechnology primarily engages in the research, production, sales, and service of in vitro diagnostic reagents and instruments, being a key supplier in the POCT field [1] - The latest quarterly report for Q1 2025 shows the company achieved revenue of 244 million yuan, a year-on-year decrease of 24.08%, and a net profit of 64.31 million yuan, down 25.24%, with a gross margin of 77.15% [1] - As of the Q1 2025 report, four institutions held shares in Jidan Biotechnology, totaling 28.14 million shares with a market value of 236 million yuan [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Jidan Biotechnology, which closed at 8.19 yuan with a rolling PE ratio of 20.57, marking a new low in 21 days, and a total market capitalization of 4.154 billion yuan [1] - The average PE ratio for the medical device industry is 51.40, with a median of 37.27, positioning Jidan Biotechnology at the 48th rank within the industry [1] - As of March 31, 2025, Jidan Biotechnology had 26,747 shareholders, a decrease of 451 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Jidan Biotechnology primarily engages in the research, production, sales, and service of in vitro diagnostic reagents and instruments, being a key supplier in the domestic in vitro diagnostic field, especially in the POCT sector [1] - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 244 million yuan, a year-on-year decrease of 24.08%, and a net profit of 64.31 million yuan, down 25.24%, with a gross margin of 77.15% [1] - The PE ratios of other companies in the industry range from 10.28 to 20.57, with Jidan Biotechnology's PE ratio being lower than the industry average and median [2]

Policy Developments - The National Medical Products Administration (NMPA) is seeking public opinions on the revised procedures for conditional approval of drug listings to improve the review and approval system [2] Drug and Device Approvals - Xuno Pharmaceutical's oral cancer drug, Abexinostat, is proposed for priority review by the NMPA, aimed at adult patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies [5] - LuKang Pharmaceutical has received the drug registration certificate for Gefitinib tablets, a first-generation targeted drug for non-small cell lung cancer with EGFR gene mutations [6] Capital Market Activities - Shenzhen Keximingde Medical Technology Co., Ltd. completed a multi-hundred million RMB A+ round financing, with funds allocated for brand building and R&D of soft endoscope products [8] - Buchang Pharmaceutical announced the abandonment of the preferential right to acquire shares in its subsidiary, Shaanxi Modern Innovation, resulting in an 86.50% ownership stake post-transfer [9] - Taiji Group plans to optimize its equity structure by acquiring stakes in its subsidiaries for a nominal price [10] Industry Developments - Chugai Pharmaceutical and Gero PTE have signed a $220 million collaboration agreement to integrate Gero's AI-driven platform into Chugai's R&D strategy for developing therapies for age-related diseases [12] - Kanghua Biotech has terminated its collaboration with Xiran Bochuang on the development of mRNA vaccines for tuberculosis, indicating a strategic shift towards in-house R&D capabilities [13] Shareholder Activities - Guizhou Jin Domain Medical Testing Group announced that major shareholder Guochuang Kaiyuan intends to reduce its stake by up to 1% through market transactions [16] - Haichuang Pharmaceutical reported that shareholder Yingchuang Power has cumulatively reduced its stake by 0.28% [17] - Tongrentang announced the resignation of its executive vice president, Zhang Chunyou, who will continue to serve in a managerial role at a subsidiary [18]

证券代码：603387 证券简称：基蛋生物 公告编号：2025-025 基蛋生物科技股份有限公司 关于公司涉及诉讼的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 是否会对上市公司损益产生影响：本案件二审已立案审查，尚未开庭， 也未产生有效判决，暂时无法判断对公司本期利润和期后利润的影响。公司将根 据诉讼进展情况及时履行信息披露义务，敬请广大投资者理性投资，注意投资风 险。 议、会计凭证、会计账簿、财务报表、审计报告及财务会计报告（包括资产负债 表、利润表、现金流量表、资产减值准备明细表、利润分配表、股东权益增减变 动表、其他有关附表）等材料交由基蛋生物查阅和复制； 2、判令基蛋生物有权委托会计师、律师等中介机构执业人员辅助进行上述 查阅和复制事宜； 3、判令本案全部诉讼费由景川诊断承担。 具体内容详见公司于 2024 年 12 月 25 日披露的《基蛋生物：关于公司涉及 诉讼的公告》（公告编号：2024-049）。 一、本次诉讼的基本情况 基蛋生物科技股份有限公司（以下简称"公司"或"基蛋生物"）作 ...